Newsfeed

Bei diesem Bereich handelt es sich um eine mögliche Darstellungsform der Integration von Nachrichtenquellen mit Bezug zu börsennotierten Unternehmen.
Als Präsentationsebene fungiert ein Template, dass an Kurznachrichtenservices angelehnt ist, bei dem sich Nutzer einen schnellen Überblick über aktuelle Nachrichten verschaffen können. Die Detailansichten ermöglichen bei Interesse weitergehende Recherchen.

Dieser Newsfeed ist eine Zusammenstellung aktueller Nachrichten, die aus Direktanbindungen von TopTier NewsWire-Services mit Bezug zu börsennotierten Unternehmen stammen. Dieser Feed hier dient ausschließlich Demonstrationszwecken. Sektoren-spezifische Nachrichten, Public Relations sowie Produktinformationen können über die GICS Portale > Bereich Sektor-Intelligence abgerufen werden.

US6402683063
Filter zurücksetzen
Do you already know our new terminal view? Click here.
FIGI: BBG000BHCYJ1
NKTR
Nektar Therapeutics
GICS: Health Care · SECTOR: Healthcare · SUB-SECTOR: Biotechnology · THEMEFOLIO: $HLTH
NAME
Nektar Therapeutics
ISIN
US6402683063
TICKER
NKTR
MIC
XNAS
REUTERS
NKTR.OQ
BLOOMBERG
NKTR US
Do., 19.03.2026       Nektar Therapeutics
US6402683063

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Nektar To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Nektar between February 26, 2025 and December 15, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner...
Zur Nachricht
Nektar Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 19.03.2026       Nektar Therapeutics
US6402683063

Alert: Claims Focus on Alleged Misrepresentations About REZOLVE-AA Patient Enrollment ComplianceNEW YORK, March 19, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP reminds purchasers of Nektar Therapeutics (NASDAQ: NKTR) securities of a pending securities class action....
Zur Nachricht
Nektar Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 19.03.2026       Nektar Therapeutics
US6402683063

New York, New York--(Newsfile Corp. - March 18, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Nektar Therapeutics (NASDAQ: NKTR) between February 26, 2025 and December 15, 2025, both dates inclusive (the "Class Period"), of the important May 5, 2026 lead plaintiff deadline.SO WHAT: If you purcha...
Zur Nachricht
Nektar Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mi., 18.03.2026       Nektar Therapeutics
US6402683063

Law Offices of Howard G. Smith reminds investors of the upcoming May 5, 2026 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Nektar Therapeutics (“Nektar” or the “Company”) (NASDAQ: NKTR) securities between February 26, 2025 and December 15, 2025, inclusive (the “Class Period”). IF YOU ARE AN INVES...
Zur Nachricht
Nektar Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mi., 18.03.2026       Nektar Therapeutics
US6402683063

Alert: Claims Focus on Alleged Misrepresentations About REZOLVE-AA Patient Enrollment ComplianceNEW YORK, March 18, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP reminds purchasers of Nektar Therapeutics (NASDAQ: NKTR) securities of a pending securities class action....
Zur Nachricht
Nektar Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mi., 18.03.2026       Nektar Therapeutics
US6402683063

New York, New York--(Newsfile Corp. - March 17, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Nektar Therapeutics (NASDAQ: NKTR) between February 26, 2025 and December 15, 2025, both dates inclusive (the "Class Period"). A class action lawsuit has already be...
Zur Nachricht
Nektar Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 17.03.2026       Nektar Therapeutics
US6402683063

Levi & Korsinsky, LLP reminds purchasers of Nektar Therapeutics (NASDAQ: NKTR) securities of a pending securities class action. THE CASE: A class action seeks to recover damages for investors who purchased Nektar securities between February 26, 2025 and December 15, 2025. YOUR OPTIONS: You may be entitled to compensation without payment of...
Zur Nachricht
Nektar Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 17.03.2026       Nektar Therapeutics
US6402683063

Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, announces that a securities fraud class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Nektar Therapeutics (“Nektar” or the “Company”) (NASDAQ: NKTR) securities between February 26, 2025 and December 15, 2025, inclusive...
Zur Nachricht
Nektar Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 17.03.2026       Nektar Therapeutics
US6402683063

NEW YORK, March 17, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Nektar Therapeutics (NASDAQ: NKTR). Shareholders who purchased shares of NKTR during the class period listed are encouraged to...
Zur Nachricht
Nektar Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 17.03.2026       Nektar Therapeutics
US6402683063

New York, New York--(Newsfile Corp. - March 16, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Nektar Therapeutics (NASDAQ: NKTR) between February 26, 2025 and December 15, 2025, both dates inclusive (the "Class Period"). A class action lawsuit has already be...
Zur Nachricht
Nektar Therapeutics
Charts & Research Termsheets Terminal
Permalink
Silent Ad
Mo., 16.03.2026       Nektar Therapeutics
US6402683063

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Nektar To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Nektar between February 26, 2025 and December 15, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner...
Zur Nachricht
Nektar Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mo., 16.03.2026       Nektar Therapeutics
US6402683063

The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of shareholders who purchased or otherwise acquired Nektar Therapeutics (“Nektar” or the “Company”) (NASDAQ: NKTR) securities between February 26, 2025 and December 15, 2025, inclusive (the “Class Period”). Nektar investors have until May 5, 2026 to fil...
Zur Nachricht
Nektar Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mo., 16.03.2026       Nektar Therapeutics
US6402683063

LOS ANGELES, March 16, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Nektar Therapeutics ("Nektar" or "the Company") (NASDAQ: NKTR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholder...
Zur Nachricht
Nektar Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mo., 16.03.2026       Nektar Therapeutics
US6402683063

New York, New York--(Newsfile Corp. - March 15, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Nektar Therapeutics (NASDAQ: NKTR) between February 26, 2025 and December 15, 2025, both dates inclusive (the "Class Period"). A class action lawsuit has already be...
Zur Nachricht
Nektar Therapeutics
Charts & Research Termsheets Terminal
Permalink
So., 15.03.2026       Nektar Therapeutics
US6402683063

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Nektar To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Nektar between February 26, 2025 and December 15, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner...
Zur Nachricht
Nektar Therapeutics
Charts & Research Termsheets Terminal
Permalink
So., 15.03.2026       Nektar Therapeutics
US6402683063

NEW YORK, March 15, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Nektar Therapeutics (NASDAQ: NKTR) between February 26, 2025 an...
Zur Nachricht
Nektar Therapeutics
Charts & Research Termsheets Terminal
Permalink
So., 15.03.2026       Nektar Therapeutics
US6402683063

New York, New York--(Newsfile Corp. - March 14, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Nektar Therapeutics (NASDAQ: NKTR) between February 26, 2025 and December 15, 2025, both dates inclusive (the "Class Period"). A class action lawsuit has already be...
Zur Nachricht
Nektar Therapeutics
Charts & Research Termsheets Terminal
Permalink
Sa., 14.03.2026       Nektar Therapeutics
US6402683063

New York, New York--(Newsfile Corp. - March 13, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Nektar Therapeutics (NASDAQ: NKTR) between February 26, 2025 and December 15, 2025, both dates inclusive (the "Class Period"). A class action lawsuit has alrea...
Zur Nachricht
Nektar Therapeutics
Charts & Research Termsheets Terminal
Permalink
Fr., 13.03.2026       Nektar Therapeutics
US6402683063

Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Nektar Therapeutics (“Nektar” or the “Company”) (NASDAQ: NKTR) securities between February 26, 2025 and December 15, 2025, inclusive (the “Class Period”). Nektar investors have until May 5, 2026 to file a lead plaintiff motion....
Zur Nachricht
Nektar Therapeutics
Charts & Research Termsheets Terminal
Permalink
Fr., 13.03.2026       Nektar Therapeutics
US6402683063

New York, New York--(Newsfile Corp. - March 12, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Nektar Therapeutics (NASDAQ: NKTR) between February 26, 2025 and December 15, 2025, both dates inclusive (the "Class Period"). A class action lawsuit has alrea...
Zur Nachricht
Nektar Therapeutics
Charts & Research Termsheets Terminal
Permalink
Silent Ad
Do., 12.03.2026       Nektar Therapeutics
US6402683063

SAN FRANCISCO, March 12, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the fourth quarter ended December 31, 2025. Cash and investments in marketable securities on December 31, 2025 were...
Zur Nachricht
Nektar Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 12.03.2026       Nektar Therapeutics
US6402683063

Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Nektar Therapeutics (“Nektar” or the “Company”) (NASDAQ: NKTR) investors concerning the Company’s possible violations of the federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON N...
Zur Nachricht
Nektar Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 12.03.2026       Nektar Therapeutics
US6402683063

NEW YORK, March 12, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Nektar Therapeutics ("Nektar" or the "Company") (NASDAQ: NKTR) and certain officers.  The class action, filed in the United States District Court for the Northern District of California, and docketed under 26-cv- 01951, is on behalf...
Zur Nachricht
Nektar Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 12.03.2026       Nektar Therapeutics
US6402683063

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Nektar To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Nektar between February 26, 2025 and December 15, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner...
Zur Nachricht
Nektar Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 12.03.2026       Nektar Therapeutics
US6402683063

Law Offices of Howard G. Smith announces an investigation on behalf of Nektar Therapeutics (“Nektar” or the “Company”) (NASDAQ: NKTR) investors concerning the Company’s possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN NEKTAR THERAPEUTICS (NKTR), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTENTI...
Zur Nachricht
Nektar Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 12.03.2026       Nektar Therapeutics
US6402683063

The Law Offices of Frank R. Cruz announces an investigation of Nektar Therapeutics (“Nektar” or the “Company”) (NASDAQ: NKTR) on behalf of investors concerning the Company’s possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON NEKTAR THERAPEUTICS (NKTR), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM...
Zur Nachricht
Nektar Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mi., 11.03.2026       Nektar Therapeutics
US6402683063

New York, New York--(Newsfile Corp. - March 11, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Nektar Therapeutics (NASDAQ: NKTR) between February 26, 2025 and December 15, 2025, both dates inclusive (the "Class Period"). A class action lawsuit has alrea...
Zur Nachricht
Nektar Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 10.03.2026       Nektar Therapeutics
US6402683063

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Nektar To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Nektar between February 26, 2025 and December 15, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner...
Zur Nachricht
Nektar Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 10.03.2026       Nektar Therapeutics
US6402683063

The DJS Law Group reminds investors of a class action lawsuit against Nektar Therapeutics (“Nektar” or “the Company”) (NASDAQ: NKTR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of NKTR during the...
Zur Nachricht
Nektar Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 10.03.2026       Nektar Therapeutics
US6402683063

The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Nektar Therapeutics (“Nektar” or “the Company”) (NASDAQ: NKTR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Inv...
Zur Nachricht
Nektar Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mo., 09.03.2026       Nektar Therapeutics
US6402683063

NEW YORK, March 9, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Nektar Therapeutics (NASDAQ: NKTR) between February 26, 2025 and...
Zur Nachricht
Nektar Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mo., 09.03.2026       Nektar Therapeutics
US6402683063

SAN DIEGO, March 9, 2026 /PRNewswire/ -- Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Nektar Therapeutics (NASDAQ: NKTR) securities between February 26, 2025 and December 15, 2025. Nektar is a biopharmaceutical company focused on discovering and developing therapies t...
Zur Nachricht
Nektar Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mo., 09.03.2026       Nektar Therapeutics
US6402683063

Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Nektar Therapeutics (NASDAQ: NKTR) between February 26, 2025 and December 15, 2025. Nektar describes itself as a “biopharmaceutical company focused on discovering and developing therapies that selectively modulate the immune...
Zur Nachricht
Nektar Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mo., 09.03.2026       Nektar Therapeutics
US6402683063

Philadelphia, Pennsylvania--(Newsfile Corp. - March 9, 2026) - WHAT IS HAPPENING? Grabar Law Office is investigating claims on behalf of shareholders of Nektar Therapeutics (NASDAQ: NKTR). The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company.If you purchased Nektar Therapeutics (NA...
Zur Nachricht
Nektar Therapeutics
Charts & Research Termsheets Terminal
Permalink
So., 08.03.2026       Nektar Therapeutics
US6402683063

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Nektar To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Nektar between February 26, 2025 and December 15, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner...
Zur Nachricht
Nektar Therapeutics
Charts & Research Termsheets Terminal
Permalink
Sa., 07.03.2026       Nektar Therapeutics
US6402683063

SAN FRANCISCO, March 6, 2026 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) today announced that, on February 20, 2026, the Organization and Compensation Committee of Nektar's Board of Directors granted non-qualified stock options to purchase an aggregate of 4,300 shares of its common stock to three newly-hired employees under Nektar's 2025 In...
Zur Nachricht
Nektar Therapeutics
Charts & Research Termsheets Terminal
Permalink
Fr., 06.03.2026       Nektar Therapeutics
US6402683063

Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Nektar Therapeutics (NASDAQ: NKTR) securities between February 26, 2025 and December 15, 2025. Nektar is a biopharmaceutical company focused on discovering and developing therapies that selectively modulate the immune syste...
Zur Nachricht
Nektar Therapeutics
Charts & Research Termsheets Terminal
Permalink
Fr., 27.02.2026       Nektar Therapeutics
US6402683063

SAN FRANCISCO, Feb. 26, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the fourth quarter and year-ended December 31, 2025 on Thursday, March 12, 2026, after the close of U.S.-based financial markets. Howard Robin, President and Chief Executive Officer, will host a conference call to review the resu...
Zur Nachricht
Nektar Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mi., 25.02.2026       Nektar Therapeutics
US6402683063

SAN FRANCISCO, Feb. 24, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that company management will be participating in the TD Cowen 46th Annual Health Care Conference taking place March 2-4, 2026 in Boston and the 2026 Jefferies Biotech on the Beach Summit taking place March 9-11, 2026 in Miami....
Zur Nachricht
Nektar Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 17.02.2026       Nektar Therapeutics
US6402683063

SAN FRANCISCO, Feb. 17, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced an academic research collaboration with the University of California, San Francisco (UCSF) and Stephen L. Hauser, M.D., Robert A. Fishman Distinguished Professor of Neurology and Director of the UCSF Weill Institute for Neurosciences. Dr. Hauser is a ne...
Zur Nachricht
Nektar Therapeutics
Charts & Research Termsheets Terminal
Permalink
Fr., 13.02.2026       Nektar Therapeutics
US6402683063

SAN FRANCISCO, Feb. 13, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on the development of innovative medicines in the field of immunotherapy, today announced the closing of its underwritten public offering of $460 million of shares of its common stock and, in lieu of common stock to certa...
Zur Nachricht
Nektar Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 12.02.2026       Nektar Therapeutics
US6402683063

SAN FRANCISCO, Feb. 11, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on the development of innovative medicines in the field of immunotherapy, today announced the pricing of its upsized underwritten public offering of $400 million of shares of its common stock and, in lieu of common stock...
Zur Nachricht
Nektar Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 10.02.2026       Nektar Therapeutics
US6402683063

SAN FRANCISCO, Feb. 10, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on the development of innovative medicines in the field of immunotherapy, today announced that it has commenced an underwritten public offering of $300,000,000 of its shares of its common stock and, in lieu of common stoc...
Zur Nachricht
Nektar Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 10.02.2026       Nektar Therapeutics
US6402683063

71% and 83% of patients maintained EASI-75 responses and 85% and 63% maintained vIGA-AD 0/1 responses with 24 µg/kg monthly and quarterly dosing, respectivelyMeaningful improvement in responses observed across key efficacy endpoints at week 52 with both monthly and quarterly dosing, including an up to 5-fold increase in EASI-100 response ratesFavo...
Zur Nachricht
Nektar Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mo., 09.02.2026       Nektar Therapeutics
US6402683063

SAN FRANCISCO, Feb. 9, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on the development of novel immunology therapies, today announced it will host an investor call and live webcast to review topline results from the 36-week maintenance period of the ongoing Phase 2b REZOLVE-AD clinical tri...
Zur Nachricht
Nektar Therapeutics
Charts & Research Termsheets Terminal
Permalink
Fr., 30.01.2026       Nektar Therapeutics
US6402683063

SAN FRANCISCO, Jan. 30, 2026 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) today announced that, on January 21, 2026, the Organization and Compensation Committee of Nektar's Board of Directors granted non-qualified stock options to purchase 1,600 shares of its common stock to one newly-hired employee under Nektar's 2025 Inducement Plan....
Zur Nachricht
Nektar Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 22.01.2026       Nektar Therapeutics
US6402683063

NEW YORK, Jan. 22, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Nektar Therapeutics ("Nektar" or the "Company") (NASDAQ: NKTR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Zur Nachricht
Nektar Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 15.01.2026       Nektar Therapeutics
US6402683063

NEW YORK, Jan. 15, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Nektar Therapeutics ("Nektar" or the "Company") (NASDAQ: NKTR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Zur Nachricht
Nektar Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 08.01.2026       Nektar Therapeutics
US6402683063

NEW YORK, Jan. 8, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Nektar Therapeutics ("Nektar" or the "Company") (NASDAQ: NKTR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Zur Nachricht
Nektar Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 01.01.2026       Nektar Therapeutics
US6402683063

NEW YORK, Jan. 1, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Nektar Therapeutics ("Nektar" or the "Company") (NASDAQ: NKTR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Zur Nachricht
Nektar Therapeutics
Charts & Research Termsheets Terminal
Permalink